AstraZeneca Reports Mixed Lung Cancer Trial Outcomes From Three Pivotal Studies
AstraZeneca reports mixed lung cancer trial data, highlighting successes for Tagrisso and Enhertu while halting a volrustomig study.
Read original at benzingaStocks · News reference
Goldman Sachs Maintains Neutral on HUTCHMED (China), Lowers Price Target to $14
Goldman Sachs analyst Paul Choi maintains HUTCHMED (China) (NASDAQ:HCM) with a Neutral and lowers the price target from $16 to $14.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 23, 2026, 4:15 PM
- Checked
- Jul 23, 2026, 4:15 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
HUTCHMED shares are trading higher after the company announced high-level results from the SAFFRON Phase III trial.
Read original at benzingaReported Sunday, HUTCHMED Says ORPATHYS Plus TAGRISSO Achieved Statistically Significant, Clinically Meaningful PFS And OS Improvements In MET-Driven EGFR-Mutated Lung Cancer
First global Phase III trial to show significant progression-free and overall survival benefits in this setting SAFFRON trial results reinforce TAGRISSO® as the backbone therapy across EGFRm lung cancer
Read original at benzingaHUTCHMED (China) H1 EPS $0.09 Down From $2.61 YoY, Sales $278.287M Up From $277.677M YoY
Read original at benzinga